Topic: pneumococcal vaccine
Pfizer posted positive top-line results for a trial of its 20-valent pneumococcal vaccine, potentially setting up a filing by the end of 2020.
Chinese drug regulators approved two domestically made vaccines, rivals to Pfizer's Prevnar 13 and Merck's and GSK's HPV shots.
As Merck and Pfizer race to market with next-gen vaccines, the companies are fighting in court over a trade secrets lawsuit from Merck.
Former NFL star Terry Bradshaw is reaching out to fellow boomers about the risk of pneumococcal pneumonia in Pfizer’s latest awareness push.
AZ's China sales jumped 25% in 2018; Pfizer Japan recalls valsartan drugs made with Mylan's API; resistance might hurt Shionogi and Roche's Xofluza.
In a phase 1/2 study, Astellas and Affinivax's MAPS-based vaccine will be tested head-to-head against Pfizer's Prevnar 13.
Merck's 15-strain pneumococcal vaccine got an FDA breakthrough tag for children, months after Pfizer's 20-valent shot won one in adults.
Racing to the market with rival Merck, Pfizer won an important FDA "breakthrough" tag for its next-gen pneumococcal vaccine candidate.
Merck is already in phase 3 testing for its next-generation pneumococcal vaccine, and Pfizer's CFO said his company is "all in" on advancing its shot.
Pfizer’s vaccines business has for years centered on Prevnar 13, the world’s bestselling vaccine, and 2017 was no exception. But the company wants to change that—and for good reason.